Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 6/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466941 | 1.00 | SMPD1 (0.44) | SMPD1FDPSFAAHCES1CES2 | |
| SCHEMBL466582 | 1.00 | SMPD1 (0.44) | SMPD1FDPSFAAHCES1CES2 | |
| SCHEMBL466752 | 1.00 | SMPD1 (0.44) | SMPD1FDPSFAAHCES1CES2 | |
| SCHEMBL466809 | 0.98 | FDPS (0.42) | SMPD1FDPSFAAHCES1CES2 | |
| SCHEMBL466712 | 0.92 | FAAH (0.51) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466646 | 0.92 | FAAH (0.51) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466851 | 0.92 | FAAH (0.51) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466745 | 0.89 | KDM4E (0.55) | FAAHCES1MEN1CYP1A2KMT2A | |
| SCHEMBL18092236 | 0.75 | CES2 (0.52) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL10824505 | 0.74 | LPAR3 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180258113-A1 | NOVEL ARTIFICIAL PHOSPHOLIPID-PROTEIN BIOCONJUGATES FOR BIOMOLECULAR RECOGNITION | ASTAKHOVA, Irina Kira (DK) | 2018-09-13 | — | — | US | claimed |
| WO-2015055630-A1 | COMPOSITIONS FOR TRANSFECTING NUCLEIC ACID MOLECULES INTO EUKARYOTIC CELLS | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2015-04-23 | — | — | WO | claimed |
| EP-2860255-A1 | Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells | Technische Universität Graz (AT) | 2015-04-15 | — | — | EP | claimed |
| US-20220296518-A1 | LIPID-BASED NANOPARTICLE DELIVERY SYSTEM FOR HYDROPHILIC CHARGED COMPOUND | NATIONAL TAIWAN UNIVERSITY (TW) | 2022-09-22 | — | — | US | disclosed |
| US-20200197306-A1 | CATIONIC LIQUID CRYSTALLINE NANOPARTICLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-25 | — | — | US | disclosed |
| WO-2019078611-A1 | NANOLIPOSOME-MICROBUBBLE CONJUGATE HAVING CAS9 PROTEIN, GUIDE RNA FOR INHIBITING EXPRESSION OF SRD5A2 GENE AND CATIONIC POLYMER COMPLEX ENCAPSULATED THEREIN, AND HAIR LOSS RELIEVING OR TREATING COMPOSITION CONTAINING SAME | 주식회사 무진메디 | 2019-04-25 | — | — | WO | disclosed |
| US-20180258113-A1 | NOVEL ARTIFICIAL PHOSPHOLIPID-PROTEIN BIOCONJUGATES FOR BIOMOLECULAR RECOGNITION | ASTAKHOVA, Irina Kira (DK) | 2018-09-13 | — | — | US | disclosed |
| US-9315828-B2 | Prompt nucleic acid delivery carrier composition | Takeuchi, Hirofumi (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9090912-B1 | Nucleic acid complex and nucleic acid-delivering composition | Takeuchi, Hirofumi (JP) | 2015-07-28 | — | — | US | disclosed |
| EP-2405001-B1 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID-DELIVERING COMPOSITION | TAKEUCHI HIROFUMI (JP) | 2015-07-08 | — | — | EP | disclosed |
| EP-2140870-B1 | PROMPT NUCLEIC ACID DELIVERY CARRIER COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2015-06-24 | — | — | EP | disclosed |
| EP-2217208-B1 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20100305190-A1 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | Takeuchi, Hirofumi (JP) | 2010-12-02 | — | — | US | disclosed |
| EP-2217208-A2 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20100063131-A1 | PROMPT NUCLEIC ACID DELIVERY CARRIER COMPOSITION | Takeuchi, Hirofumi (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100034749-A1 | Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases | MEDIGENE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-2140870-A1 | PROMPT NUCLEIC ACID DELIVERY CARRIER COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090258923-A1 | Carrier Composition for Nucleic Acid Transport | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| WO-2009061003-A2 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-14 | — | — | WO | disclosed |
| EP-1946761-A1 | CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258113-A1 | NOVEL ARTIFICIAL PHOSPHOLIPID-PROTEIN BIOCONJUGATES FOR BIOMOLECULAR RECOGNITION | PEBP1, PLTP, PHOSPHO1 | SMPD1 53/4885FDPS 2395/4885FAAH 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.